Before the availability of next-generation sequencing (NGS) technologies, the mutational status of RAS oncogenes (NRAS and KRAS), the two most prevalent mutated genes in MM, and of the tumor suppressor TP53, had been explored in pPCL using traditional DNA sequencing methodologies. This evidence concerns the gene KRAS and Miyoshi myopathy.